onin2downin2 Thursday, 10/11/18 06:04:38 AM Re: Murph1953 post# 72 Post # of 87 Thanks for an informative and interesting hour. I know very little about anything, but my ignorance of Biology was no barrier to slipstreaming Genentec in buying a small amount of Affimed. Betting on their analysis, I figured $5 billion a reasonable valuation. Juno Therapeutics had similar issues, but was ultimately acquired by Celgene for $9 billion. They settled for $24 million in a class action for not immediately disclosing 3 deaths in a trial.